Abstract
This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX®, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5% in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.
| Original language | English |
|---|---|
| Journal | Survey of Ophthalmology |
| Volume | 50 |
| Issue number | 6 SUPPL. 1 |
| DOIs | |
| State | Published - Nov 1 2005 |
Fingerprint
Keywords
- Anti-infectives
- Antibiotic
- Moxifloxacin
- Penetration
- Potency
- Safety
- Therapy
- VIGAMOX®
ASJC Scopus subject areas
- Ophthalmology
Cite this
Ophthalmic infections and their anti-infective challenges. / Alfonso, Eduardo C; Crider, Julie.
In: Survey of Ophthalmology, Vol. 50, No. 6 SUPPL. 1, 01.11.2005.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ophthalmic infections and their anti-infective challenges
AU - Alfonso, Eduardo C
AU - Crider, Julie
PY - 2005/11/1
Y1 - 2005/11/1
N2 - This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX®, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5% in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.
AB - This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX®, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5% in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.
KW - Anti-infectives
KW - Antibiotic
KW - Moxifloxacin
KW - Penetration
KW - Potency
KW - Safety
KW - Therapy
KW - VIGAMOX®
UR - http://www.scopus.com/inward/record.url?scp=27844546833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27844546833&partnerID=8YFLogxK
U2 - 10.1016/j.survophthal.2005.05.001
DO - 10.1016/j.survophthal.2005.05.001
M3 - Article
VL - 50
JO - Survey of Ophthalmology
JF - Survey of Ophthalmology
SN - 0039-6257
IS - 6 SUPPL. 1
ER -